Read more for which batches are affected.
Please check your stock and return affected batches to the original supplier.
Pfizer states that the problem with the affected batches relates to sealing of the Uniject™ injection device. They advise that use of the impacted product has an unlikely probability of being associated with adverse events and the potential risk to patients is considered to be negligible.
Any adverse reactions should be reported as usual via the Yellow Card Scheme.
You can access the statement below.